These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 1704999)

  • 1. Induction of thymidylate synthase associated with multidrug resistance in human breast and colon cancer cell lines.
    Chu E; Drake JC; Koeller DM; Zinn S; Jamis-Dow CA; Yeh GC; Allegra CJ
    Mol Pharmacol; 1991 Feb; 39(2):136-43. PubMed ID: 1704999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines.
    Johnston PG; Drake JC; Trepel J; Allegra CJ
    Cancer Res; 1992 Aug; 52(16):4306-12. PubMed ID: 1643628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and quantitation of thymidylate synthase mRNA in human colon adenocarcinoma cell line resistant to 5-fluorouracil by competitive PCR.
    Shibata J; Aiba K; Shibata H; Minowa S; Horikoshi N
    Anticancer Res; 1998; 18(3A):1457-63. PubMed ID: 9673356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma.
    Chu E; Koeller DM; Johnston PG; Zinn S; Allegra CJ
    Mol Pharmacol; 1993 Apr; 43(4):527-33. PubMed ID: 8474431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line.
    Chu E; Zinn S; Boarman D; Allegra CJ
    Cancer Res; 1990 Sep; 50(18):5834-40. PubMed ID: 1697502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil.
    Copur S; Aiba K; Drake JC; Allegra CJ; Chu E
    Biochem Pharmacol; 1995 May; 49(10):1419-26. PubMed ID: 7763285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates.
    Longley DB; Boyer J; Allen WL; Latif T; Ferguson PR; Maxwell PJ; McDermott U; Lynch M; Harkin DP; Johnston PG
    Cancer Res; 2002 May; 62(9):2644-9. PubMed ID: 11980662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
    van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
    Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance.
    Subbarayan PR; Sarkar M; Nelson G; Benitez E; Singhal S; Ardalan B
    Anticancer Res; 2010 Apr; 30(4):1149-56. PubMed ID: 20530421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell cycle regulation of the G0/G1 transition in 5-fluorouracil-sensitive and -resistant human colon cancer cell lines.
    McGinn CJ; Pestalozzi BC; Drake JC; Glennon MC; Kunugi K; Otterson G; Allegra CJ; Johnston PG; Kinsella TJ
    Cancer J; 2000; 6(4):234-42. PubMed ID: 11038143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil.
    Matsuoka K; Tsukuda K; Suda M; Kobayashi K; Ota T; Okita A; Watanabe K; Suzuki E; Murakami M; Doihara H; Shimizu N
    Int J Oncol; 2004 Jan; 24(1):217-22. PubMed ID: 14654960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA.
    Chu E; Lai GM; Zinn S; Allegra CJ
    Mol Pharmacol; 1990 Sep; 38(3):410-7. PubMed ID: 2402230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks.
    Wang W; McLeod HL; Cassidy J; Collie-Duguid ES
    Cancer Chemother Pharmacol; 2007 May; 59(6):839-45. PubMed ID: 17119966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of cytotoxicity with prolonged exposure to fluorouracil in human colon cancer cells.
    Ren Q; Van Groeningen CJ; Hardcastle A; Aherne GW; Geoffroy F; Allegra CJ; Johnston PG; Grem JL
    Oncol Res; 1997; 9(2):77-88. PubMed ID: 9167189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.
    Wang W; Marsh S; Cassidy J; McLeod HL
    Cancer Res; 2001 Jul; 61(14):5505-10. PubMed ID: 11454699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of retinoblastoma protein and E2F-1 transcription factor in the acquisition of 5-fluorouracil resistance by colon cancer cells.
    Obama K; Kanai M; Kawai Y; Fukushima M; Takabayashi A
    Int J Oncol; 2002 Aug; 21(2):309-14. PubMed ID: 12118326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection of thymidylate synthase mRNA in 5-fluorouracil resistant human colon adenocarcinoma cells].
    Shibata J; Aiba K; Shibata H; Minowa S; Horikoshi N
    Gan To Kagaku Ryoho; 1994 Aug; 21(10):1613-8. PubMed ID: 8060136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells.
    Akman SA; Forrest G; Chu FF; Esworthy RS; Doroshow JH
    Cancer Res; 1990 Mar; 50(5):1397-402. PubMed ID: 2406012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules.
    Aschele C; Sobrero A; Faderan MA; Bertino JR
    Cancer Res; 1992 Apr; 52(7):1855-64. PubMed ID: 1532346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
    Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
    Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.